Structure-based inhibitory peptide design targeting peptide-substrate binding site in EGFR tyrosine kinase

Area of Science:

• Oncology
• Molecular Biology
• Computational Chemistry

Background:

• Epidermal growth factor receptor (EGFR) is crucial for cell functions but its aberrant activation drives cancers like non-small cell lung carcinoma (NSCLC).
• The L858R mutation in EGFR is a common oncogenic driver in NSCLC, often resistant to existing therapies.
• MIG6 acts as a natural feedback inhibitor of EGFR by promoting its degradation.

Purpose of the Study:

• To computationally design and evaluate peptides targeting the L858R mutant EGFR.
• To identify novel inhibitors for EGFR mutations unresponsive to current treatments.

Main Methods:

• In silico molecular docking, molecular dynamics (MD) simulation, and MM-PBSA calculations were employed.
• A library of 31 peptides, based on MIG6 structure, was designed and screened.
• Physicochemical properties of designed peptides were assessed.

Main Results:

• Two designed peptides demonstrated selective inhibition of the EGFRL858R mutant.
• The study identified specific peptide inhibitors for a clinically relevant EGFR mutation.

Conclusions:

• This computational approach successfully identified potential peptide inhibitors for oncogenic EGFR mutants.
• These findings may guide the development of new therapeutic peptides for EGFR-mutated NSCLC.